References
- Doggrell SA. Tolvaptan (Otsuka). Curr Opin Invest Drugs. 2004;5(9):977–983.
- Pharmaceuticals and Medical Devices Agency website [Internet]. Samsca tablets (tolvaptan) [package insert]. Japan: Otsuka Pharmaceutical Co., Ltd; 2021 [cited 2021 May 18]. Available from: https://www.info.pmda.go.jp/go/pack/2139011D1022_1_09/?view=frame&style=XML&lang=ja
- U.S. Food and Drug Administration website [Internet]. SAMSCA tablets (tolvaptan) [label]. Japan: Otsuka Pharmaceutical Co., Ltd; 2021 [cited 2021 May 18]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022275s016lbledt.pdf
- U.S. Food and Drug Administration website [Internet]. JYNARQUE tablets (tolvaptan) [label]. Japan: Otsuka Pharmaceutical Co., Ltd; 2021 [cited 2021 May 18]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/204441s008lbl.pdf
- Health Canada website [Internet]. SAMSCA (tolvaptan) [product monograph]. Japan: Otsuka Pharmaceutical Co., Ltd; 2021 [cited 2021 May 18]. Available from: https://pdf.hres.ca/dpd_pm/00051954.PDF
- Health Canada website [Internet]. JINARC (tolvaptan) [product monograph]. Japan: Otsuka Pharmaceutical Co., Ltd; 2021 [cited 2021 May 18]. Available from: https://pdf.hres.ca/dpd_pm/00053695.PDF
- European Medicines Agency website [Internet]. Samsca tablets (tolvaptan) [summaries of product characteristics]. Japan: Otsuka Pharmaceutical Co., Ltd; 2021 [cited 2021 May 18]. Available from: https://www.ema.europa.eu/en/documents/product-information/samsca-epar-product-information_en.pdf
- European Medicines Agency website [Internet]. Jinarc tablets (tolvaptan) [summaries of product characteristics]. Japan: Otsuka Pharmaceutical Co., Ltd; 2021 [cited 2021 May 18]. Available from: https://www.ema.europa.eu/en/documents/product-information/jinarc-epar-product-information_en.pdf
- Kinugawa K, Sato N, Inomata T, et al. Novel risk score efficiently prevents Tolvaptan-induced hypernatremic events in patients with heart failure. Circ J. 2018;82(5):1344–1350.
- Hirai K, Shimomura T, Moriwaki H, et al. Risk factors for hypernatremia in patients with short- and long-term tolvaptan treatment. Eur J Clin Pharmacol. 2016;72(10):1177–1183.
- Torres VE, Chapman AB, Devuyst O, et al. TEMPO:4 trial investigators. tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med. 2012;367(25):2407–2418.
- Makabe S, Mochizuki T, Mitobe M, et al. Elevation of the serum liver enzyme levels during tolvaptan treatment in patients with autosomal dominant polycystic kidney disease (ADPKD). Clin Exp Nephrol. 2018;22(5):1079–1087.
- Khan MY, Rawala MS, Siddiqui M, et al. Tolvaptan-induced liver injury: who is at risk? A case report and literature review. Cureus. 2019;11(6):e4842.
- Sato I, Yamamoto Y, Kato G, et al. Potentially inappropriate medication prescribing and risk of unplanned hospitalization among the elderly: a self-matched, case-crossover study. Drug Saf. 2018;41(10):959–968.
- Imai S, Momo K, Kashiwagi H, et al. Prescription of colchicine with other dangerous concomitant medications: a nation-wide survey using the Japanese Claims Database. Biol Pharm Bull. 2020;43(10):1519–1525.
- Imai S, Momo K, Kashiwagi H, et al. A cross-sectional exploratory survey on occurrence of triple-whammy prescription pattern in Japan. Int J Clin Pharm. 2020;42(5):1369–1373.
- JMDC website [Internet]. JMDC claims database. Japan: JMDC Inc; 2021 [cited 2021 Feb 1]. Available from: https://www.jmdc.co.jp/jmdc-claims-database
- Kim HY. Statistical notes for clinical researchers: chi-squared test and Fisher’s exact test. Restorative Dent Endod. 2017;42(2):152–155.
- Inomata T, Ikeda Y, Kida K, et al. Effects of additive tolvaptan vs. increased furosemide on heart failure with diuretic resistance and renal impairment - results from the K-STAR Study. Circ J. 2017;82(1):159–167.
- Tzoulis P, Waung JA, Bagkeris E, et al. Real-life experience of tolvaptan use in the treatment of severe hyponatraemia due to syndrome of inappropriate antidiuretic hormone secretion. Clin Endocrinol (Oxf). 2016;84(4):620–626.
- Nasuhara Y, Sakushima K, Oki H, et al. Analysis of the implementation of blood tests specified in the package insert after prescription of thiamazole. J Patient Saf. 2020;16(1):24–29.